SkinBioTherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of SkinBioTherapeutics generated cash of -$2,726,316, which is less than the previous year. Cash used in financing activities reached the amount of $4,511,978 last year. Net change in cash is therefore -$510,930.
Cash Flow
| 2016 | -1.16K | -136.21K | 394.04K |
|---|---|---|---|
| 2018 | -667.74K | -72.26K | 0 |
| 2020 | -892.13K | -73.67K | 0 |
| 2021 | -1.55M | -112.30K | 4.11M |
| 2023 | -2.64M | -165.27K | 2.31M |
| 2024 | -2.72M | -2.29M | 4.51M |
SBTX.L Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 1.31M | 1.80M | 2.15M | 3.12M | 3.92M | 19.74K |
Operating activities | ||||||
Net income | -2.94M | -2.83M | -1.43M | -1.50M | -844.41K | -4.20K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 175.97K | 44.19K | 5.05K | 5.1K | 0 | 0 |
Stock-based compensation expense | 0 | 1.27K | 61.25K | 155.81K | 71.85K | 0 |
| Deferred income tax benefit | 0 | 1.27K | 61.25K | 155.81K | 71.85K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 166.84K | -54.73K | -198.32K | 171.95K | 57.76K | -30.60K |
Inventories | 96.41K | 89.07K | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 16.95K | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -2.72M | -2.64M | -1.55M | -892.13K | -667.74K | -1.16K |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -28.17K | -89.79K | -112.30K | -73.66K | -72.26K | -136.21K |
Acquisitions Net | -1.59M | 0 | 0 | -5 | 0 | 0 |
Cash generated by investing activities | -2.29M | -165.27K | -112.30K | -73.67K | -72.26K | -136.21K |
Financing activities | ||||||
Common Stock Issued | 3.11M | 2.35M | 4.12M | 0 | 0 | 394.04K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 1.47M | 0 | -2.92K | 0 | 0 | 0 |
Cash used in financing activities | 4.51M | 2.31M | 4.11M | 0 | 0 | 394.04K |
Net Change In Cash | -510.93K | -493.08K | 2.45M | -965.81K | -740.00K | 236.92K |
Cash at end of period | 800.90K | 1.31M | 4.60M | 2.15M | 3.18M | 256.66K |
| Data source | Data source | Data source | Data source | Data source | Data source |